ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Disagree

<< Previous

Bullboard Posts

Next >>

Comment by DavidKingCanadaon Oct 13, 2021 10:29am

291 Views

Post# 34000757

RE:RE:Disagree

Well let's do some Math

431,000,000 Shares Outstanding

10:1 43,100,000
15:1 28,733,000
20:1 21,550,000
25:1 17,240,000

I believe a 10:1 will be reasonable.
At a Nasdaq Listing of $4.00 we can see the Marketcap at 172,000,000 meaning double from the current Marketcap.

<< Previous

Bullboard Posts

Next >>

Day trading vs. swing trading strategies for small-cap stocks